Viatris Inc.’s newly christened interchangeable biosimilar Semglee (insulin glargine-yfgn) will move to preferred status on pharmacy benefit manager Express Scripts’ largest national formulary for 2022, in what could be an important commercial advance for the nearly 14 month-old product.
Semglee was awarded interchangeability with Sanofi’s Lantus by the US Food and Drug Administration in July, about a year after it was first approved as a biosimilar. (Also see...